vs
Side-by-side financial comparison of CSW INDUSTRIALS, INC. (CSW) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $233.0M, roughly 1.5× CSW INDUSTRIALS, INC.). HAEMONETICS CORP runs the higher net margin — 13.2% vs 4.4%, a 8.8% gap on every dollar of revenue. On growth, CSW INDUSTRIALS, INC. posted the faster year-over-year revenue change (20.3% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $22.7M). Over the past eight quarters, CSW INDUSTRIALS, INC.'s revenue compounded faster (5.1% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CSW vs HAE — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $233.0M | $339.0M |
| Net Profit | $10.3M | $44.7M |
| Gross Margin | 39.7% | 59.7% |
| Operating Margin | 7.4% | 19.9% |
| Net Margin | 4.4% | 13.2% |
| Revenue YoY | 20.3% | -2.7% |
| Net Profit YoY | -61.9% | 19.3% |
| EPS (diluted) | $0.62 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $233.0M | $339.0M | ||
| Q3 25 | $277.0M | $327.3M | ||
| Q2 25 | $263.6M | $321.4M | ||
| Q1 25 | $230.5M | $330.6M | ||
| Q4 24 | $193.6M | $348.5M | ||
| Q3 24 | $227.9M | $345.5M | ||
| Q2 24 | $226.2M | $336.2M | ||
| Q1 24 | $210.9M | — |
| Q4 25 | $10.3M | $44.7M | ||
| Q3 25 | $40.7M | $38.7M | ||
| Q2 25 | $40.9M | $34.0M | ||
| Q1 25 | $35.1M | $58.0M | ||
| Q4 24 | $26.9M | $37.5M | ||
| Q3 24 | $36.1M | $33.8M | ||
| Q2 24 | $38.6M | $38.4M | ||
| Q1 24 | $31.8M | — |
| Q4 25 | 39.7% | 59.7% | ||
| Q3 25 | 43.0% | 59.5% | ||
| Q2 25 | 43.8% | 59.8% | ||
| Q1 25 | 44.2% | 58.4% | ||
| Q4 24 | 41.4% | 55.5% | ||
| Q3 24 | 45.6% | 54.2% | ||
| Q2 24 | 47.5% | 52.0% | ||
| Q1 24 | 44.4% | — |
| Q4 25 | 7.4% | 19.9% | ||
| Q3 25 | 20.5% | 17.9% | ||
| Q2 25 | 20.8% | 16.8% | ||
| Q1 25 | 19.5% | 21.6% | ||
| Q4 24 | 15.3% | 16.9% | ||
| Q3 24 | 22.6% | 15.0% | ||
| Q2 24 | 24.3% | 11.8% | ||
| Q1 24 | 21.0% | — |
| Q4 25 | 4.4% | 13.2% | ||
| Q3 25 | 14.7% | 11.8% | ||
| Q2 25 | 15.5% | 10.6% | ||
| Q1 25 | 15.2% | 17.5% | ||
| Q4 24 | 13.9% | 10.8% | ||
| Q3 24 | 15.8% | 9.8% | ||
| Q2 24 | 17.1% | 11.4% | ||
| Q1 24 | 15.1% | — |
| Q4 25 | $0.62 | $0.95 | ||
| Q3 25 | $2.41 | $0.81 | ||
| Q2 25 | $2.43 | $0.70 | ||
| Q1 25 | $2.05 | $1.17 | ||
| Q4 24 | $1.60 | $0.74 | ||
| Q3 24 | $2.26 | $0.66 | ||
| Q2 24 | $2.47 | $0.74 | ||
| Q1 24 | $2.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.2M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $1.1B | $911.5M |
| Total Assets | $2.3B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.2M | $363.4M | ||
| Q3 25 | $31.5M | $296.4M | ||
| Q2 25 | $38.0M | $292.9M | ||
| Q1 25 | $225.8M | $306.8M | ||
| Q4 24 | $213.8M | $320.8M | ||
| Q3 24 | $273.2M | $299.3M | ||
| Q2 24 | $18.9M | $344.4M | ||
| Q1 24 | $22.2M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | $800.1M | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $166.0M | — |
| Q4 25 | $1.1B | $911.5M | ||
| Q3 25 | $1.1B | $849.2M | ||
| Q2 25 | $1.1B | $882.3M | ||
| Q1 25 | $1.1B | $820.8M | ||
| Q4 24 | $1.0B | $906.9M | ||
| Q3 24 | $1.0B | $878.9M | ||
| Q2 24 | $650.2M | $905.4M | ||
| Q1 24 | $615.7M | — |
| Q4 25 | $2.3B | $2.5B | ||
| Q3 25 | $1.5B | $2.4B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.4B | $2.5B | ||
| Q4 24 | $1.4B | $2.5B | ||
| Q3 24 | $1.4B | $2.5B | ||
| Q2 24 | $1.1B | $2.5B | ||
| Q1 24 | $1.0B | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | 0.75× | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $93.6M |
| Free Cash FlowOCF − Capex | $22.7M | $87.2M |
| FCF MarginFCF / Revenue | 9.8% | 25.7% |
| Capex IntensityCapex / Revenue | 2.6% | 1.9% |
| Cash ConversionOCF / Net Profit | 2.81× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $162.0M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.9M | $93.6M | ||
| Q3 25 | $61.8M | $111.3M | ||
| Q2 25 | $60.6M | $17.4M | ||
| Q1 25 | $27.3M | $116.6M | ||
| Q4 24 | $11.6M | $43.8M | ||
| Q3 24 | $66.8M | $48.8M | ||
| Q2 24 | $62.7M | $-27.4M | ||
| Q1 24 | $22.4M | — |
| Q4 25 | $22.7M | $87.2M | ||
| Q3 25 | $58.7M | $106.3M | ||
| Q2 25 | $57.7M | $13.6M | ||
| Q1 25 | $22.8M | $100.9M | ||
| Q4 24 | $8.5M | $35.2M | ||
| Q3 24 | $61.3M | $39.4M | ||
| Q2 24 | $59.6M | $-33.1M | ||
| Q1 24 | $17.5M | — |
| Q4 25 | 9.8% | 25.7% | ||
| Q3 25 | 21.2% | 32.5% | ||
| Q2 25 | 21.9% | 4.2% | ||
| Q1 25 | 9.9% | 30.5% | ||
| Q4 24 | 4.4% | 10.1% | ||
| Q3 24 | 26.9% | 11.4% | ||
| Q2 24 | 26.3% | -9.8% | ||
| Q1 24 | 8.3% | — |
| Q4 25 | 2.6% | 1.9% | ||
| Q3 25 | 1.1% | 1.5% | ||
| Q2 25 | 1.1% | 1.2% | ||
| Q1 25 | 2.0% | 4.7% | ||
| Q4 24 | 1.6% | 2.5% | ||
| Q3 24 | 2.4% | 2.7% | ||
| Q2 24 | 1.4% | 1.7% | ||
| Q1 24 | 2.3% | — |
| Q4 25 | 2.81× | 2.09× | ||
| Q3 25 | 1.52× | 2.88× | ||
| Q2 25 | 1.48× | 0.51× | ||
| Q1 25 | 0.78× | 2.01× | ||
| Q4 24 | 0.43× | 1.17× | ||
| Q3 24 | 1.85× | 1.44× | ||
| Q2 24 | 1.62× | -0.71× | ||
| Q1 24 | 0.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
